RxDoctor Payments Data

William Jonas, MD

Hematology & Oncology · Atlanta, GANPI 1962443051

Payments from drug & device makers

$27,952in general payments, 2019–2025

Across 407 payments — averaging $68.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8K
  • Beigene USA, Inc.$3K
  • AstraZeneca$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • TG Therapeutics, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$18,30465%
  • Travel & lodging$8483%
  • Food & beverage$8,64031%
  • Education$1601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis29$8,178
Beigene USA, Inc.10$3,441
AstraZeneca26$2,545
E.r. Squibb & Sons, L.L.C.11$2,177
TG Therapeutics, Inc.1$1,665
Takeda Pharmaceuticals U.S.A., Inc.8$1,623
R-pharm US LLC3$1,335
Pfizer27$584
Sanofi18$459
Merck22$454
AbbVie17$359
Genentech USA, Inc.23$356
Seagen Inc.21$332
Eisai Inc.15$315
Daiichi Sankyo Inc.14$299
Amgen14$295
Gilead(2 entities)15$283
Johnson & Johnson(2 entities)13$238
Boston Scientific5$237
GSK8$172
Intera Oncology, Inc1$153
Rigel Pharmaceuticals, Inc.7$151
Astellas Pharma US Inc7$149
Pharmacyclics LLC, An Abbvie Company7$149
GT Medical Technologies, Inc1$140
Biocompatibles, Inc.1$139
Stryker2$137
Legend Biotech USA Inc.5$124
Array Biopharma Inc10$108
Bristol Myers Squibb5$104
Incyte Corporation5$101
Epizyme, Inc.6$100
Intuitive Surgical1$96
Adaptive Biotechnologies Corporation4$72
Regeneron Healthcare Solutions, Inc.3$61
Bayer3$55
Beone Medicines USA, Inc.2$54
ADC Therapeutics America, Inc.3$54
Servier Pharmaceuticals LLC3$50
EMD Serono, Inc.2$49
Genmab U.S., Inc.2$43
Mirati Therapeutics, Inc.2$40
G1 Therapeutics, Inc.2$39
Azurity Pharmaceuticals, Inc.1$34
Karyopharm Therapeutics Inc.2$30
Mckesson Specialty Care Distribution, LLC1$29
Iovance Biotherapeutics, Inc.1$27
Jazz Pharmaceuticals Inc.1$27
Pharmaessentia USA Corporation1$25
Exelixis Inc.1$22
Geron Corporation1$21
Stemline Therapeutics Inc.1$20
Syndax Pharmaceuticals, Inc.1$20
Boehringer Ingelheim1$19
Tempus AI, Inc1$19
Lilly USA, LLC1$18
Helsinn Therapeutics (U.S.), Inc.1$18
Puma Biotechnology, Inc.1$17
Coherus Oncology, Inc.1$17
Portola Pharmaceuticals, LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,952 in reported general payments places this provider in the 65th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$4,757,949
Medicare patients
832
Services billed
170,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate80$1,345,339
RevlimidLenalidomide62$985,995
ImbruvicaIbrutinib50$802,019
BrukinsaZanubrutinib37$512,323
CalquenceAcalabrutinib Maleate35$483,308
KisqaliRibociclib Succinate17$261,312
XtandiEnzalutamide15$204,895
JakafiRuxolitinib Phosphate12$199,520
Lenalidomide14$196,988
IbrancePalbociclib12$180,281
EliquisApixaban152$110,275
XareltoRivaroxaban50$55,588
Exemestane50$4,210
ValacyclovirValacyclovir Hcl116$3,721
Anastrozole161$2,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$2,545$1,828,647115 claims
Bristol Myers SquibbRevlimid$104$985,99562 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$149$802,01950 claims
Beigene USA, Inc.Brukinsa$3,441$512,32337 claims
PfizerIbrance, Eliquis$584$290,556164 claims
NovartisKisqali$8,178$261,31217 claims
Astellas Pharma US IncXtandi$149$204,89515 claims
Incyte CorporationJakafi$101$199,52012 claims
Johnson & JohnsonXarelto$238$55,58850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →